Cornea

Dr Brianna Rhue, OD, FAAO, FSLS details her upcoming presentation "Cutting Out Surgery for the Management of Refractive Error," where she will detail the underutilization of orthokeratology during Vision Expo East 2024 later this week.

Ferroptosis is a form of cell death that depends on the presence of iron in the cells.

Barry Eiden, OD, FAAO, FSLS, sits down with Optometry Times to highlight the importance of staying up-to-date with technology in the development of treatment and diagnosis of keratoconus and what's to come at this year's IKA Keratoconus Symposium in May.

Oluwatosin U Smith, MD, urges consideration of the interaction between corneal and glaucomatous disease whenever treating glaucoma or corneal issues during the annual Glaucoma 360 meeting in San Francisco, California.

OKYO Pharma announced the acceptance of OK-101 as an investigational new drug following clinical studies investigating the candidate in patients with neuropathic corneal pain, the first to do so.

The study, based out of India, successfully transplanted 32 of 34 corneas harvested from drowning victims.

Much has changed in the study of keratoconus over the years.

Damon Dierker, OD, FAAO, shares latest updates in research on sutureless cryopreserved amniotic membrane for moderate-to-severe dry eye with short treatment duration.

Earlier this year, Aurion’s cell therapy received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for the management of bullous keratopathy, marking the first regulatory approval in the world for an allogeneic cell therapy to manage corneal endothelial disease.

Hear how the Clek study continues to play a role in today's keratoconus care.

Private practice eye care providers’ ability to immediately administer antibiotic eye drops or have them overnighted to the patient is a giant step forward for practice and patient.

The ‘all-in-one’ platform combines specialized imaging and three new FDA-approved apps with a focus on metrics, corneal imaging, and cataract care.

Justin Schweitzer, OD, FAAO, discusses his talk, "Current trends in keratoconus management," at Vision Expo West 2023 in Las Vegas, Nevada.

Combination therapy may reduce adverse events related to corticosteroids alone.

In this part 2 of the pediatric myopia and keratoconus series, Drs Chan and Swartz dive into ortho-k and crosslinking in children.

Treatment requires a systematic, multifaceted approach to improve outcomes.

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

The use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases in the study.

At NOA 2023 in Fort Lauderdale, Florida, Rhea Magee, OD, presented a pediatric patient case as part of the Resident Grand Rounds.

Jacobi Cleaver, OD, FAAO, caught up with Optometry Times to talk about his presentation on neurotrophic keratits, which he discussed at the National Optometric Association in Fort Lauderdale, Florida.

Pierce Kenworthy, OD, gives the crowd at NOA 2023 an in-depth look at the cornea and all the dangers that could befall it. He details what clinicians should look for and when to refer to an ophthalmologist for surgery.

Keratopigmentation technique offers therapeutic and cosmetic applications.

At the AOA Optometry's Meeting 2023, Jonathan Etter, MD, FAAO, presented with Susan Gromacki, OD, MS, FAAO, FSLS, on the OD and MD perspectives on keratoconus and collagen crosslinking.

Jacqueline Theis, OD, FAAO, shares insights from her AOA 2023 presentation on treating neurologic dry eye.

Melissa Barnett, OD, FAAO, FSLS, FBCLA, shares insights from her AOA 2023 presentation on managing keratoconus in clinical practice.

At the AOA Optometry's Meeting 2023, Jonathan Etter, MD, FAAO, presented with Susan Gromacki, OD, MS, FAAO, FSLS, on the OD and MD perspectives on keratoconus and collagen crosslinking.

Andrew Morgenstern, OD, FAAO, FNAP, gives a brief history of the International Keratoconus Academy of Eye Care Professionals.

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.